**Supplementary Appendix**

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People with Coronary Heart Disease and Impaired Glucose Tolerance: the ACE Study Group

Table S1: Participant Information Available Within the Last 12 Months of Follow-up 2

Table S2: Baseline Characteristics for the On-Treatment Cohort 3

Figure S1: Kaplan Meier Plots (On-Treatment Analysis)

 A: Incident Diabetes 4

 B: Regression to Normoglycemia (WHO criteria) 5

 C: Regression to Normoglycemia (ADA criteria) 6

**Table S1: Participant Information Available Within the Last 12 Months of Follow-up**

|  |  |  |  |
| --- | --- | --- | --- |
|  | AcarboseN (%) | PlaceboN (%) | TotalN (%) |
| Randomized | 3272 | 3250 | 6522 |
| Diagnosis of Diabetes | 436 (13.3%) | 513 (15.8%) | 946 (14.5%) |
| Normal OGTT (i.e., FPG < 7.0 mmol/l and 2HRG < 11.1 mmol/l) | 1396 (42.7%) | 1323 (40.7%) | 2719 (41.7%) |
| No OGTT but FPG < 7 mmol/l or unconfirmed FPG ≥ 7 mmol/l | 723 (22.1%) | 672 (20.7%) | 1394 (21.4%) |
| No OGTT or FPG  | 717 (21.9%) | 742 (22.8%) | 1459 (22.4%) |

**Table S2: Baseline Characteristics for the On-Treatment Cohort**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Acarbose** | **Placebo** | **P** |
| N | 3254 | 3236 |  |
| Age (years)\* | 64.4 (8.1) | 64.3 (8.0) | 0.56 |
| Females\* | 871 (26.8) | 883 (27.3) | 0.64 |
| Weight (kg)\* | 70.0 (10.7) | 70.3 (11.0) | 0.27 |
| BMI (kgm2)\* | 25.3 (3.1) | 25.5 (3.1) | 0.051 |
| Systolic BP (mmHg)\* | 130 (14.3)  | 129 (14.1) | 0.11 |
| Diastolic BP (mmHg)\* | 78 (9.2) | 78 (9.2) | 0.31 |
| FPG (mmol/l)\* | 5.5 (0.86) | 5.5 (0.78) | 0.48 |
| 2 hour PG (mmol/L)\* | 9.3 (1.1) | 9.3 (1.1) | 0.99 |
| HbA1c (%)/mmol/mol\* | 5.9 (0.8)/41 (8) | 5.9 (0.7)/41 (7) | 0.84 |
| IGT only | 2686 (82.5) | 2651 (81.9) | 0.62 |
| IGT + IFG  | 568 (17.5) | 584 (18.1) | 0.53 |
| Thiazide diuretic  | 97 (3.0) | 91 (2.8) | 0.68 |
| ACEi or ARB\* | 1921 (59.1) | 1903 (58.9)  | 0.82 |
| Beta blocker\* | 2131 (65.6) | 2152 (66.6) | 0.42 |
| Calcium channel blocker\*  | 963 (29.6) | 935 (28.9) | 0.52 |
| Statin\* | 3023 (93.0) | 3017 (93.3) | 0.69 |
| \*data marked with an asterisk have been reported previously10; data are expressed as mean (SD) or N (%) unless otherwise noted. FPG – fasting plasma glucose; IGT – impaired glucose tolerance; IFG - Impaired fasting glucose (FPG 6.1-6.99 mmol/L); ACEi – Angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker |

**Figure S1 A: Kaplan Meier plot of the time to incident diabetes (on-treatment analysis)**

****

**Figure S1 B: Kaplan Meier plots of the time to first occurrence of regression to normoglycemia using the WHO criteria for normoglycemia (on-treatment analysis)
**

**Figure S1 C:**  **Kaplan Meier plots of the time to first occurrence of regression to normoglycemia using the ADA criteria for normoglycemia (on-treatment analysis) **